Group 1 - The core viewpoint of the article highlights the recent decline in the stock price of Guangzhou Kingmed Diagnostics Group Co., Ltd., which has dropped for six consecutive trading days, with a cumulative decline of -3.19% [1] - Kingmed Diagnostics is a high-tech service enterprise focused on third-party medical testing and pathological diagnosis, aiming to provide leading medical diagnostic information integration services to healthcare institutions across the country [1] - The financial report indicates that Huabao Fund's Huabao CSI Medical ETF is among the top ten shareholders of Kingmed Diagnostics, having reduced its holdings in the first quarter of this year [1] Group 2 - The performance data shows that the year-to-date return for the Huabao CSI Medical ETF is 0.77%, ranking 2451 out of 3422 in its category [2] - The ETF's performance over various periods includes a near-term decline of -0.57% over the past week and a quarterly increase of 7.44% [2] - The average performance of similar funds over the same periods indicates a better performance compared to the Huabao CSI Medical ETF, with an average year-to-date return of 5.48% [2] Group 3 - The fund manager of Huabao CSI Medical ETF is Hu Jie, who has extensive experience in the financial sector, having joined Huabao Fund Management in June 2006 and currently serving as the Director of Index Investment [4][5] - Hu Jie has managed multiple funds over her career, including the Huabao CSI Medical Index Fund and the Huabao CSI 1000 Index Fund, showcasing her expertise in index-based investment strategies [4][5] - Huabao Fund Management Company was established in March 2003 and is led by Chairman Huang Kongwei and General Manager Xiang Hui, with three main shareholders [5]
金域医学连跌6天,华宝基金旗下1只基金位列前十大股东